BioWorld

Aug. 15, 2005

View Archived Issues

THP's Transgenic Rabbits To Make Polyclonal Drugs

Read More

BioVeris Licenses Exclusive Vaccine Rights From Baxter

Read More

U.S. Patent Disclosures

Read More

Other News To Note

Read More

Alexion Raises $67M As Lead Drugs Near End Of Phase III

Just days after Alexion Pharmaceuticals Inc. said it completed enrollment in a pivotal trial of its cardiovascular drug, pexelizumab, ahead of schedule, the company priced a public offering to raise $66.9 million. (BioWorld Today) Read More

$33M Financing, Loans Could Take Xenogen To Profitability

Read More